2014 Conferences

Dr. Jan Burger from the MD Anderson Cancer Center spoke to me about his research on ibrutinib resistance in chronic lymphocytic leukemia at the ASH (American Society of Hematology) Annual Meeting in December 7, 2014. TAKE AWAY POINTS: The number of patients with resistance to ibrutinib is small, but

Dr. William Wierda from the MD Anderson Cancer Center was interviewed about the pipeline of new targeted therapies for CLL at the 18th International Congress On Hematologic Malignancies held in New York City in February 2014. TAKE AWAY POINTS: The major groups of inhibitors target BTK or phosphatidylinositol 3-kinase